IL6 and early-onset autosomal dominant Alzheimer disease: Moreover, earlier, Fedorova and co-authors showed that marinobufagenin treatment of mice with Alzheimer’s disease (AD) significantly decreased the inflammatory marker interleukin-6 (IL-6) mRNA in the cortex, which was higher in the AD mice than in wild-type mice [23].